Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data.

ABSTRACT:

Background

Data on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on pancreatic cancer incidence are limited and inconsistent. Here we evaluate the association of GLP-1RAs, alone and in combinations, with incident pancreatic cancer risk in a real-world population, stratified by obesity and smoking status.

Methods

This retrospective cohort included patients with type 2 diabetes mellitus who were prescribed GLP-1RAs or other nonglucagon-like peptide-1 receptor agonist antidiabetes medications between January 2013 and March 2019 and had no prior diagnosis of pancreatic cancer. The incident (first-time) diagnosis of pancreatic cancer during a 5-year follow-up was compared between propensity-score matched cohorts of patients prescribed GLP-1RAs vs other nongl

SUBMITTER: Wang L 

PROVIDER: S-EPMC11884861 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature